Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
Holding IRON?
Track your performance easily
IRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.60 - $77.60
Previous Close$47.35
Volume147.94K
Average Volume (3M)265.95K
Market Cap
$1.41B
Enterprise Value$908.41M
Total Cash (Recent Filing)$500.94M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 07, 2024EPS Estimate
-$1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.66
Shares Outstanding29,725,763
10 Day Avg. Volume151,469
30 Day Avg. Volume265,950
Standard Deviation0.22
R-Squared0.02
Alpha-0.00563
Financial Highlights & Ratios
Price to Book (P/B)2.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-23.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-10.97
Forecast
1Y Price Target
$61.00Price Target Upside28.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Disc Medicine News
PremiumPre-Earnings
Is IRON a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated analyses from the Phase 2 AURORA trial showed that treatment with bitopertin in erythropoietic protoporphyria patients elicited a meaningful impact on key aspects of EPP, providing more insights into the drug’s disease modifying effect.
Financial PositionThe company’s current cash position of $500.9M is expected to fund its planned operational plans into 2027.
Market OpportunityThe commercial opportunity of MF CKD associated anemia is huge, and there is no effective treatment to-date.
Bears Say
Clinical DataMixed or negative clinical data raises concerns about the effectiveness of the company's treatments.
Financial PerformanceR&D expenses jumped 94.1% YoY to $23.5M from $12.1M, indicating significantly higher spending without guaranteed returns.
Regulatory ChallengesConvincing the FDA to accept PPIX reduction as a primary endpoint could be difficult and unlikely.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $25.60 and its highest was $77.60 in the past 12 months.
What is Disc Medicine’s market cap?
Currently, no data Available
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Aug 08, 2024. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.104 by $0.074.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -$1.06.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 29,725,763 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.104. Following the earnings report the stock price went up 3.828%.
Which hedge fund is a major shareholder of Disc Medicine?
Among the largest hedge funds holding Disc Medicine’s share is Deerfield Management Company, LP. It holds Disc Medicine’s shares valued at 46M.
---
Disc Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.00 (28.02% Upside)
$61.00 (28.02% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 241.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.66%
12-Months-Change
Fundamentals
Return on Equity
-21.16%
Trailing 12-Months
Asset Growth
32.81%
Trailing 12-Months
Company Description
Disc Medicine
FS Development Corp is a blank check company.
---
IRON Stock 12 Month Forecast
Average Price Target
$61.00
▲(28.02% Upside)
Technical Analysis
Best Analysts Covering IRON
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+5.17%
reiterated a buy rating 3 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +5.17% per trade.
---